Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease which results in thickening and scarring of the interstitial tissue. As the only 2 Food and Drug Administration (FDA)-approved medications on the market, it is valuable to compare the impact of nintedanib and pirfenidone on c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ipatova, Anastasia Y, Koerner, Pamela H, Miller, Richard T, Staskon, Francis, Radi, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416683/
https://www.ncbi.nlm.nih.gov/pubmed/30890862
http://dx.doi.org/10.1177/1179548419834922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416683/
https://www.ncbi.nlm.nih.gov/pubmed/30890862
http://dx.doi.org/10.1177/1179548419834922

Ejemplares similares